Document is current

Article History

Received: 2 May 2020

Revised: 5 June 2020

Accepted: 10 August 2020

First Online: 14 August 2020

Compliance with ethical standards

:

: Khadija Ba, Barbara Casolla, François Caparros, Nicolas Bricout, Lucie Della Schiava, Marco Pasi, Nelly Dequatre-Ponchelle, Marie Bodenant, Régis Bordet, and Hilde Hénon report no disclosure. Charlotte Cordonnier reports participation in symposia organized by Boehringer-Ingelheim and advisory board by BMS (honoraria paid to Adrinord); she is vice-president of the European Stroke Organisation (unpaid), member of DSMBs for institutional trials (ATTEST 2, UK; FIV-HeMA, France) (unpaid); and she received research support from the French Ministry of Health (A3ICH trial); she is associate editor of Stroke. Didier Leys reports participation in symposia organized by Boehringer Ingelheim, Bayer, BMS and Pfizer (honoraria paid to Adrinord). He is editor of-in-chief of the European Journal of Neurology (honoraria paid to Adrinord), vice president of the scientific committee of the <i>Fondation de Recherche sur les AVC</i> (unpaid) member of the scientific committee of the Servier Institute (unpaid) and was member of DSMBs for institutional trials (unpaid) (INCH, Germany; TARDIS, UK; and TO-ACT, the Netherlands). He received research support from a grant of the University of Heidelberg (Germany) for the ECASS4 trial (paid to the hospital).

: The registry was approved by the relevant ethical committee (<i>Comité de Protection des Personnes Nord Ouest IV Lille, France</i>, March 9th, 2010, registration number 10.677). Patients were managed according to local rules without any investigation or treatment specifically performed for the purpose of this study. Patients gave consent themselves or via a close relative for the follow-up.